# PT-141: Research Overview — My Peptide Solution > A literature summary of PT-141 (bremelanotide), the FDA-approved melanocortin-receptor agonist for hypoactive sexual desire disorder in premenopausal women. Covers mechanism, Phase 3 trial results, and cited safety cautions. Bremelanotide, an FDA-approved melanocortin-receptor agonist for hypoactive sexual desire disorder in premenopausal women — with a real Phase 3 trial record and real, common side effects. ## The short version PT-141 (bremelanotide) is a synthetic cyclic peptide that activates melanocortin receptors in the brain rather than blood vessels in the body. That is its defining difference from the erectile-dysfunction drugs most people have heard of: instead of relaxing blood vessels, it is thought to act on hypothalamic circuits that govern sexual desire and arousal. It is FDA-approved — but only for one specific indication: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, as an as-needed injection. Two identical Phase 3 trials in more than 1,200 women found it produced a statistically significant improvement in sexual desire over placebo [20]. It also has a real, well-documented side-effect profile: nausea affects a large share of users, and it is not approved for men or for postmenopausal women, whatever off-label use might suggest online. This page describes what was studied and labeled — not a use case for anyone outside it. ## What it is PT-141 is a synthetic cyclic heptapeptide — a seven-amino-acid ring closed by a lactam bridge — built as an analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Its full sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It is structurally related to melanotan II, a compound sometimes discussed for tanning, but with the C-terminal amide swapped for a carboxylic acid, which changes its receptor behavior. Its approved-drug name is bremelanotide, and the FDA-approved formulation is a 1.75 mg subcutaneous injection used as needed, no more than once every 24 hours and no more than eight times a month, with a terminal half-life of roughly 2.7 hours [22]. ## How it works PT-141 activates central melanocortin receptors — chiefly MC4R, and to a lesser extent MC3R — concentrated in the hypothalamus and limbic system, brain regions involved in motivation and reward. Human fMRI work in women with HSDD found that MC4R agonism increased sexual desire for up to 24 hours and altered brain activity in response to erotic stimuli, including enhanced connectivity between the amygdala and insula and increased cerebellar and motor-cortex activity [19]. Notably, a 2025 hamster study found that neither low nor high doses changed melanocortin-receptor expression in the brain's dopamine-reward circuit, and PT-141 did not enhance the rewarding quality of sexual interaction in that model — a reminder that its mechanism is not simply "more reward signal," and the full picture of how it produces its effect is still being worked out [18]. ## What the research shows *Phase 3 efficacy.* Two identical randomized, double-blind, placebo-controlled trials (RECONNECT, n=1,267 premenopausal women with HSDD) found that as-needed subcutaneous bremelanotide 1.75 mg produced a statistically significant improvement in sexual desire (an integrated score change of +0.35, P<.001) and a reduction in desire-related distress (P<.001) versus placebo over 24 weeks [20]. *Long-term follow-up.* A 52-week open-label extension enrolling 684 of those women found no new safety signals and sustained improvement in desire. The most common drug-related side effects were nausea (40.4%), flushing (20.6%), and headache (12.0%) [21]. *Brain mechanism in humans.* A randomized, placebo-controlled crossover fMRI study of 31 premenopausal women with HSDD found MC4R agonism significantly increased desire for up to 24 hours and measurably changed brain processing of erotic stimuli [19]. *A more cautious animal finding.* In female Syrian hamsters, bremelanotide did not enhance sexual reward in a conditioned-place-preference test, and receptor expression in the brain's dopamine-reward pathway was unchanged regardless of dose — a nuanced result suggesting the desire effect may not run through the classic reward circuit [18]. *Regulatory record.* The FDA prescribing information documents the approved 1.75 mg as-needed dose, its short 2.7-hour half-life, its excretion pathway, and a warning about transient blood-pressure increases that contraindicate use in uncontrolled hypertension or known cardiovascular disease [22]. ## Reported effects, cautions & safety People using PT-141 — both within its approved population and in off-label and research-use communities — describe a consistent set of effects. **These are anecdotal, not clinical evidence**, drawn from patient-review sites, forums, and clinic accounts, not controlled measurement. The most consistent report is a felt increase in sexual desire that people describe as starting in the head rather than the body — "wanting" returning before any physical change. Greater physical arousal and sensitivity, easier or more intense orgasm, and, in off-label male use, spontaneous erections are also frequently described, along with a delayed onset of a half-hour to a few hours that can last well into the next day. A real and recurring counter-report: some people say it did little or nothing for them while they still experienced the side effects — response is described as highly individual. On the adverse side, nausea is by far the most common complaint and the most likely reason people stop, typically starting within half an hour and lasting a couple of hours, worst on the first dose. Flushing and warmth, headache, injection-site irritation, and — with frequent repeated dosing — darkening of skin, gums, or moles are also described, tied to the same pigment-cell receptors PT-141 activates. The cited cautions matter here because this compound actually is FDA-approved, with a defined boundary: it is approved only for premenopausal women with HSDD, and everything else — male use, postmenopausal use, performance enhancement — is off-label [20][22]. The label itself warns of a transient blood-pressure rise that rules out use in uncontrolled hypertension or known cardiovascular disease [22]. Nausea affects a large share of users over long-term use and is a leading cause of discontinuation [21]. Rare liver-enzyme changes have also been noted in postmarketing safety monitoring, and — as with the unapproved compounds on this map — material sold as a "research chemical" version sits outside any quality-control system. ## Where it fits in Research Peptide Fundamentals PT-141 is the desire-focused entry on this map, and one of only two compounds here — alongside [tirzepatide](/tirzepatide) — with FDA approval and a real Phase 3 trial record behind it [20][22]. That puts it in a different evidentiary category from [BPC-157](/bpc-157), [CJC-1295](/cjc-1295), and [MOTS-c](/mots-c), all of which remain unapproved research chemicals with far thinner human data. But approval does not mean unlimited use: PT-141's approval is narrow — one population, one indication — and reading it against the comparison page makes clear how much of its real-world use runs ahead of what was actually studied. See the [comparison page](/compare). ![PT-141 research illustration — abstract cool scientific motif](/images/pt-141.webp) --- My Peptide Solution states plainly what the published research does and doesn't support — it is not a clinic, not a supplier, and not a substitute for a licensed clinician's judgment.